These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24577503)

  • 1. MRI can detect nigral volume loss in patients with Parkinson's disease: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Parkinsons Dis; 2014; 4(3):405-11. PubMed ID: 24577503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease.
    Kashihara K; Shinya T; Higaki F
    J Clin Neurosci; 2011 Aug; 18(8):1093-6. PubMed ID: 21719292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease.
    Lehéricy S; Bardinet E; Poupon C; Vidailhet M; François C
    Mov Disord; 2014 Nov; 29(13):1574-81. PubMed ID: 25308960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The difference in putamen volume between MSA and PD: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Parkinsonism Relat Disord; 2014 Aug; 20(8):873-7. PubMed ID: 24844749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging assessment of substantia nigral iron deposition in Parkinson's disease: a meta-analysis.
    Liu GL; Zhang HW; Zha CB; Fan TW; Chen ST; Shen TT; He K
    Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):899-906. PubMed ID: 38375696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.
    Geng DY; Li YX; Zee CS
    Neurosurgery; 2006 Feb; 58(2):256-62; discussion 256-62. PubMed ID: 16462479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease.
    Mahlknecht P; Krismer F; Poewe W; Seppi K
    Mov Disord; 2017 Apr; 32(4):619-623. PubMed ID: 28151553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
    Wang C; Fan G; Xu K; Wang S
    Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion tensor imaging of nigral degeneration in Parkinson's disease: A region-of-interest and voxel-based study at 3 T and systematic review with meta-analysis.
    Schwarz ST; Abaei M; Gontu V; Morgan PS; Bajaj N; Auer DP
    Neuroimage Clin; 2013; 3():481-8. PubMed ID: 24273730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study.
    Menke RA; Scholz J; Miller KL; Deoni S; Jbabdi S; Matthews PM; Zarei M
    Neuroimage; 2009 Aug; 47(2):435-41. PubMed ID: 19447183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease.
    O'Neill J; Schuff N; Marks WJ; Feiwell R; Aminoff MJ; Weiner MW
    Mov Disord; 2002 Sep; 17(5):917-27. PubMed ID: 12360540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
    Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging.
    Cho ZH; Oh SH; Kim JM; Park SY; Kwon DH; Jeong HJ; Kim YB; Chi JG; Park CW; Huston J; Lee KH; Jeon BS
    Mov Disord; 2011 Mar; 26(4):713-8. PubMed ID: 21506148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis.
    Licker V; Turck N; Kövari E; Burkhardt K; Côte M; Surini-Demiri M; Lobrinus JA; Sanchez JC; Burkhard PR
    Proteomics; 2014 Mar; 14(6):784-94. PubMed ID: 24449343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.
    Atasoy HT; Nuyan O; Tunc T; Yorubulut M; Unal AE; Inan LE
    Neurol India; 2004 Sep; 52(3):332-7. PubMed ID: 15472421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease.
    Banati RB; Daniel SE; Blunt SB
    Mov Disord; 1998 Mar; 13(2):221-7. PubMed ID: 9539333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.